Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.

ABSTRACT:

Importance

Clinical trials in Alzheimer disease (AD) generally allow participants to continue receiving concomitant medications, including cholinesterase inhibitors (ChEIs) and memantine, if the dose is stable. Previous analysis of observational studies indicates such individuals experience greater rate of decline on cognitive testing than those not receiving such medications.

Objective

To investigate whether concomitant use of ChEIs or memantine is associated with cognitive outcomes in AD clinical trials.

Data sources

Meta-database of 18 studies from the Alzheimer Disease Cooperative Study and Alzheimer Disease Neuroimaging Initiative.

Study selection

All studies with data on ChEI and memantine use that included assessment of specified outcome measures.

Dat

SUBMITTER: Kennedy RE 

PROVIDER: S-EPMC6324361 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature